75 77 However, a recently described ver Ffentlichten phase I / II data from a center78, 79 similar effects abrupt withdrawal of four patients, and 2 weeks off after fifth patient devolled in the study between October 2007 and February 2009, the Mayo Clinic in Rochester reported a high drop-out rate: 51%, 72% and 89% at 1, 2 and 3, respectively.78 In October 2011, 18 patients died and five patients . The survival rate showed no significant difference between CAL-101 GS-1101 the beneficiaries and Ruxolitinib a cohort of 410 receivers Ngern the standard of care among their PMF w During the last decade. In contrast, the MD Anderson Cancer Center reported that 107 patients were enrolled in the Phase I / II, 58 yet received a median of 32 months.82 Ruxolitinib In December 2011, 33 patients, including 19 off for study and no reasons were killed in related to treatment, and nine patients had leukemia mie transformation, four of them from developing study. With log-rank analysis, the patients survive Cyclooxygenas Ruxolitinib l significantly singer than in a historical cohort of 310 patients with standard therapy or research that met the phase h Tte treated I / II enrollment criteria.83 survive the receiver singer Ruxolitinib high risk was also significantly l singer than that of high-risk patients in the control group. Patients continue to be pursued. Differences in the results between the cohorts in both centers, the efficacy of therapy is related less than the Mayo Clinic in Rochester because of the lower doses and shorter therapy.83 two Phase III studies, the study controlled insulated with myelofibrosis oral JAK1 / JAK2 inhibitors I and II have been completed and are in progress. I COMFORT is a double-blind controlled EEA against placebo, which recruited 309 adult patients with MF in the United States, Canada and Australia. Patients were randomized to receive either placebo Ruxolitinib. The base line of the peripheral blood platelet count was the Ruxolitinib initiated at 15 mg / bid, or 20 mg / bid. Dose adjustment was w in line with the observations on the effectiveness and safety Were admitted during the study, as defined by the protocol. at week 24, 41.9% and 0.7% of patients who Ruxolitinib or placebo, a reduction of $ 35% spleen volume from baseline achieved, such as MRI or CT tomography.76, 77 judges Ver changes the symptoms were shaped by my myelofibrosis symptoms evaluation I changed symptom measured v2.0 Total Score.84 Ruxolitinib In my arms and placebo, 45.9% and 5.3% patients had at least a 50% improvement in mean TSS TSS improved increased by 46. 1% in the Ruxolitinib and hte 41.8% in the placebo group. All the symptoms Analyzed in my individual score sheet myelofibrosis symptoms Evaluated in patients me improve Ruxolitinib and increased in the placebo group recipients.76, 77 The same trends of improving occupational safety and Erm igungen In the spleen were in the sub-groups according to the type MF observed IPSS risk group, age, JAK2V617F mutation status, L length of the base rate palpable and anf ngliche H hemoglobin level.85 Lebensqualit t was of the Europ European Organization for Research and Treatment of Cancer Quality of Life improved Lebensqualit t Questionnaire .86 with the reduction of 87 patients symptoms.